+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality



Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality



Annals of Oncology 21(Suppl. 3): Iii83-Iii89



Although prostate cancer has recently registered increasing incidence and decreasing mortality in Spain, no analysis has yet been made of these two indicators to ascertain the magnitude of and reasons for these trends. The time trend in invasive prostate cancer incidence from 1975 to 2004 was studied by combining data from 13 Spanish population-based cancer registries. Change-point Poisson regression models were fitted for all men and for two age groups (45-64 and 65+ years). Age-period-cohort models were used to study cohort and period effects. In addition, we studied the time trend in prostate cancer mortality in Spain for the period 1980-2007. Incidence increased annually by 1.3% from 1975 to 1990 and by 7.3% thereafter. Until 1990, the percentage increase was low and indeed similar for both age groups. While the subsequent increase in the two age groups was greater, this was particularly marked among the youngest men, with a decrease being observed in age groups >85 years in the last quinquennium. Mortality increased by an annual figure of 0.7% until 1998, after which it decreased by 3.6% per annum until 2007. Despite the dramatic rise in incidence from 1990 onwards, mainly due to opportunistic screening, prostate cancer mortality was only observed to decline slowly from 1998. If prostate-specific antigen screening remains at a similar level in Spain, overdiagnosis may well become an important chronic side-effect and health problem.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055240014

Download citation: RISBibTeXText

PMID: 20427365

DOI: 10.1093/annonc/mdq087


Related references

Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. Cmaj Open 4(1): E73-E79, 2016

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urologic Clinics of North America 29(1): 173-181, 2002

Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. European Journal of Cancer Prevention 10(5): 425-428, 2001

Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction: A registry-based study in southeastern Netherlands, 1971-1995. European Journal of Cancer 34(5): 705-709, 1998

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. Journal of the National Cancer Institute 91(12): 1033-1039, 1999

Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection. Urologia Internationalis 82(3): 270-275, 2009

Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. Journal of Urology 158(2): 502-504, 1997

Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute 94(13): 981-990, 2002

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of Urology 170(1): 313-314, 2003

Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. Journal of Urology 163(2): 503-510, 2000

Prostate cancer incidence, mortality, total and free prostate specific antigen. Hellenic Journal of Nuclear Medicine 12(2): 106-109, 2009

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Bju International 109(11): 1627-1635, 2012

Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. European Urology 61(5): 865-874, 2012

Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. Urology 76(2): 436-441, 2010

Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Research 61(15): 5857-5860, 2001